Fluxome Raises VC Funds

Fluxome Sciences AS of Denmark has raised EUR 13 million in new VC funding. Capricorn Venture Partners was joined by return backers Seventure Partners, Incuba Venture and Vectata AS. Fluxome has developed a microbial metabolic engineering technology platform to build cell factories for the production of nutraceutical ingredients.

 

PRESS RELEASE

In a European biotech investment environment under pressure, fast-growing Danish biotech company Fluxome Sciences A/S announces a capital increase of DKK 100 mio/EUR 13 mio.

The DKK 100 mio/EUR 13 mio capital increase has been secured through a continued strong commitment from current investors SEVENTURE Partners (France), INCUBA Venture (Denmark), VECATA A/S (Denmark) and the addition of one of Europe's leading cleantech funds, Capricorn Cleantech Fund, managed by CAPRICORN Venture Partners (Belgium), to the group of share holders.

 

“I am very satisfied with the strengthening of our capital foundation and panel of investors”, Chairman of the Board of Fluxome Sciences, Erik H